The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study
1. 系统已在2026-03-16 16:46:38对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
E Niv, T Naftali, R Hallak, N Vaisman
Clinical nutrition, 2005
Elsevier
BACKGROUND: It was suggested that the intestinal microflora may play a role in the pathogenesis of irritable bowel syndrome (IBS). Probiotics may ease symptoms in IBS patients by changing gut microflora, reducing mucosal inflammation and exerting antibacterial effects. AIM: To assess the short-and long-term effects of Lactobacillus reuteri administration on clinical symptoms of IBS. METHODS: This is a double blind, placebo-controlled 6-month trial. Subjects consumed 1× 108cfu/tablet twice a day. The clinical …
